Literature DB >> 10980449

A diverse set of oligomeric class II MHC-peptide complexes for probing T-cell receptor interactions.

J R Cochran1, L J Stern.   

Abstract

BACKGROUND: T-cells are activated by engagement of their clonotypic cell surface receptors with peptide complexes of major histocompatibility complex (MHC) proteins, in a poorly understood process that involves receptor clustering on the membrane surface. Few tools are available to study the molecular mechanisms responsible for initiation of activation processes in T-cells.
RESULTS: A topologically diverse set of oligomers of the human MHC protein HLA-DR1, varying in size from dimers to tetramers, was produced by varying the location of an introduced cysteine residue and the number and spacing of sulfhydryl-reactive groups carried on novel and commercially available cross-linking reagents. Fluorescent probes incorporated into the cross-linking reagents facilitated measurement of oligomer binding to the T-cell surface. Oligomeric MHC-peptide complexes, including a variety of MHC dimers, trimers and tetramers, bound to T-cells and initiated T-cell activation processes in an antigen-specific manner.
CONCLUSION: T-cell receptor dimerization on the cell surface is sufficient to initiate intracellular signaling processes, as a variety of MHC-peptide dimers differing in intramolecular spacing and orientation were each able to trigger early T-cell activation events. The relative binding affinities within a homologous series of MHC-peptide oligomers suggest that T-cell receptors may rearrange in the plane of the membrane concurrent with oligomer binding.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10980449     DOI: 10.1016/s1074-5521(00)00019-3

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  9 in total

1.  T-cell activation by soluble MHC oligomers can be described by a two-parameter binding model.

Authors:  J D Stone; J R Cochran; L J Stern
Journal:  Biophys J       Date:  2001-11       Impact factor: 4.033

2.  Expression of HLA-DP0401 molecules for identification of DP0401 restricted antigen specific T cells.

Authors:  Junbao Yang; Laurel Huston; Deanna Berger; Nancy A Danke; Andrew W Liu; Mary L Disis; William W Kwok
Journal:  J Clin Immunol       Date:  2005-09       Impact factor: 8.317

Review 3.  Synthetic multivalent ligands as probes of signal transduction.

Authors:  Laura L Kiessling; Jason E Gestwicki; Laura E Strong
Journal:  Angew Chem Int Ed Engl       Date:  2006-04-03       Impact factor: 15.336

Review 4.  Class II major histocompatibility complex tetramer staining: progress, problems, and prospects.

Authors:  Sabrina S Vollers; Lawrence J Stern
Journal:  Immunology       Date:  2008-03       Impact factor: 7.397

5.  Species- and cell type-specific interactions between CD47 and human SIRPalpha.

Authors:  Shyamsundar Subramanian; Ranganath Parthasarathy; Shamik Sen; Eric T Boder; Dennis E Discher
Journal:  Blood       Date:  2005-11-15       Impact factor: 22.113

6.  Functional mutation of multiple solvent-exposed loops in the Ecballium elaterium trypsin inhibitor-II cystine knot miniprotein.

Authors:  Richard H Kimura; Douglas S Jones; Lei Jiang; Zheng Miao; Zhen Cheng; Jennifer R Cochran
Journal:  PLoS One       Date:  2011-02-18       Impact factor: 3.240

Review 7.  Critical parameters for design and development of multivalent nanoconstructs: recent trends.

Authors:  Avijit Kumar Bakshi; Tanweer Haider; Rahul Tiwari; Vandana Soni
Journal:  Drug Deliv Transl Res       Date:  2022-01-11       Impact factor: 5.671

8.  Model for the peptide-free conformation of class II MHC proteins.

Authors:  Corrie A Painter; Anthony Cruz; Gustavo E López; Lawrence J Stern; Zarixia Zavala-Ruiz
Journal:  PLoS One       Date:  2008-06-11       Impact factor: 3.240

Review 9.  Receptor Pre-Clustering and T cell Responses: Insights into Molecular Mechanisms.

Authors:  Mario Castro; Hisse M van Santen; María Férez; Balbino Alarcón; Grant Lythe; Carmen Molina-París
Journal:  Front Immunol       Date:  2014-04-30       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.